There are currently 834 clinical trials in Indianapolis, Indiana looking for participants to engage in research studies. Trials are conducted at various facilities, including Indiana University, Indiana University Melvin and Bren Simon Cancer Center, Riley Hospital for Children and Indiana University Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
NCT00920972
Recruiting
The hypothesis for this study is that a preparative regimen that maximizes host immunosuppression without myeloablation will be well tolerated and sufficient for engraftment of donor hematopoietic cells. It is also to determine major toxicities from these conditioning regimens, within the first 100 days after transplantation.
Gender:
ALL
Ages:
20 years and below
Trial Updated:
07/19/2024
Locations: Indiana University School of Medicine, Indianapolis, Indiana
Conditions: Metabolic Disorders, Hematologic, Immune, or Bone Marrow Disorders, Hemoglobinopathies, Non-malignant Disorders
Register for Updates
rTMS to Target Neural Connectivity and Rumination in Treatment-Resistant Depression
NCT06511544
Recruiting
The goal of this clinical trial is to learn if Transcranial Magnetic Stimulation (TMS) to part of the brain called the ventromedial prefrontal cortex (VMPFC) can treat a symptom called rumination in adults with major depression that has not responded to at least one medication trial. The main question it aims to answer are: Does TMS to the VMPFC change brain activity on functional magnetic resonance imaging (fMRI) during a negative self-referential processing task in adults with depression? Doe... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/15/2024
Locations: Goodman Hall Neuroscience Center, Indianapolis, Indiana
Conditions: Depression, Treatment Resistant
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana +8 locations
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
Evaluation of a Monofocal Intraocular Lens
NCT06428955
Recruiting
The aim of this study is to investigate the 3-month visual performance of the CT LUCIA 621P IOL, a hydrophobic aspheric monofocal IOL with a non-constant aspheric optic profile in adult patients 50 years of age or older who are undergoing cataract surgery.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/19/2024
Locations: Price Vision Group, Indianapolis, Indiana
Conditions: Cataract
Register for Updates
Eliminating Monitor Overuse Trial (EMO Trial)
NCT05132322
Recruiting
The purpose of this study is to identify the optimal deimplementation strategies for an overused practice: continuous pulse oximetry monitoring of children hospitalized with bronchiolitis who are not receiving supplemental oxygen.
Gender:
ALL
Ages:
2 months and above
Trial Updated:
06/03/2024
Locations: Riley Hospital for Children at IU Health, Indianapolis, Indiana
Conditions: Bronchiolitis Acute Viral
Register for Updates
High-Intensity, Dynamic-stability Gait Training in People With Multiple Sclerosis
NCT05735691
Recruiting
The goal of this clinical trial is to improve walking speed, balance, and walking in the community for people with multiple sclerosis. This trial involves intense exercise combined with walking on a shaky treadmill. Walking on a shaky treadmill helps to practice balance and intense exercise promotes the ability to walk faster and farther. In this study, participants will train with a combination of high or low intensity, and with a stable or shaky treadmill. Walking speed and endurance, balance... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/03/2024
Locations: Rehabilitation Hospital of Indiana, Indianapolis, Indiana
Conditions: Multiple Sclerosis
Register for Updates
Abbott DBS Post-Market Study of Outcomes for Indications Over Time
NCT04071847
Recruiting
The purpose of this international study is to evaluate long-term safety and effectiveness of Abbott deep brain stimulation (DBS) systems for all indications, including Parkinson's disease, essential tremor or other disabling tremor and dystonia.
Gender:
ALL
Ages:
All
Trial Updated:
05/24/2024
Locations: Indiana University, Indianapolis, Indiana
Conditions: Movement Disorders, Parkinson Disease, Essential Tremor, Tremor, Dystonia, Primary Dystonia, Secondary Dystonia
Register for Updates
Clinical Data Registry of Amblyopia Patients on Luminopia Treatment
NCT06429280
Recruiting
Amblyopia is the most prevalent cause of reduced monocular visual acuity in children and young adults, with estimates of prevalence ranging from 1% to 5%. The most common associated amblyogenic risk factors are uncorrected anisometropia, strabismus, or a combination of these. In addition to reduced visual acuity, amblyopic patients may also have measurable dysfunction of accommodation, fixation, binocularity, vergence, reading fluency, depth perception, and contrast sensitivity. For the first t... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/20/2024
Locations: Riley Children's Hospital at IU Health, Indianapolis, Indiana
Conditions: Amblyopia
Register for Updates
PVI to Prevent S. Aureus SSI After Fixation of HELEF (POTENT Study)
NCT05763602
Recruiting
The purpose of this study is to see whether applying povidone iodine (PVI) to the noses of patients undergoing lower extremity (leg, ankle, or foot) orthopedic fixation procedures of high-energy lower extremity fractures (HELEF) will decrease the patients' risk of surgical site infections (SSI), particularly those caused by Staphylococcus aureus.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2024
Locations: University of Indiana, Indianapolis, Indiana
Conditions: Surgical Site Infection
Register for Updates
A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALace)
NCT05813678
Recruiting
This is a 10-year multi-center, global, observational study to further characterize the safety profile of pegvaliase, including hypersensitivity reactions, long-term safety and tolerability, and the effectiveness of the additional risk minimization measures (aRMMs) (European Union (EU) only) in subjects receiving pegvaliase for the treatment of PKU. Subjects for whom a clinical decision has been made that they will receive pegvaliase to treat their PKU within 30 days following the date of enroll... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/10/2024
Locations: Indiana University School of Medicine, Indianapolis, Indiana
Conditions: Phenylketonuria (PKU)
Register for Updates
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
NCT05797831
Recruiting
This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have achieved complete response or partial response on chemotherapy. The study will be conducted in 2 parts. Part 1 will evaluate safety and efficacy of two different doses of navtemadlin alongside an observational control arm to determine the Phase 3 navtemadlin dose. Part 2 will evaluate the efficacy and safety of navtemadlin Phase 3 dose compared to placebo.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: Indiana University, Indianapolis, Indiana
Conditions: Endometrial Cancer
Register for Updates
The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis
NCT05564936
Recruiting
ME\&MG is a standalone software (digital solution) running on patients smartphones, connected to a web portal for physicians. It is intended to be used as an unsupervised digital self-assessment tool for the monitoring of disabilities in patients living with MG. ME\&MG contains digital active tests for the assessment of ptosis, breathing, dysarthria, upper- and lower-limb (arms and legs) weakness, treatment follow-up, and validated e-questionnaires related to daily activities, pain, fatigue, sl... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
04/23/2024
Locations: Indiana University Health, Indianapolis, Indiana
Conditions: Myasthenia Gravis
Register for Updates